- About
-
Projects
-
Column 1
- Advancing Regulatory Science
- Animal Health & Veterinary Medicine
- Expanded Access
- FDA Patient Listening Sessions
-
Column 2
- Food & Nutrition
- Improving Access to FDA Information
- Research
- Substance Use Disorders
-
Column 1
- News and Events
- Expanded Access eRequest
Coverage
The Blueprint’s four strategic goals are shaped by input from across the animal health community, including findings from the Reagan-Udall Foundation's Transforming Animal Health in the U.S. for the 21st Century report and the AVMA MUMS Roundtable…
This sustained political advocacy culminated in the formal endorsement of the FDA’s new Project Trailblazer initiative, a milestone heavily shaped by collaborative efforts between BIO’s regulatory teams and the Reagan-Udall Foundation in Washington.
The Reagan-Udall Foundation for the FDA just released a new report on strengthening early-stage drug development in the United States.
On May 27, 2026, the Reagan-Udall Foundation for the FDA, working alongside ARPA-H and the XPRIZE Foundation, ran a full-day public meeting on gerotherapeutic drug and biologic development.
Researchers from the University of California San Diego have found that U.S. overdose death rates declined dramatically between 2023 and 2024, marking the first recorded drop in all four waves of the nation’s overdose crisis.
At the Vitalist Bay longevity conference, dreamers and entrepreneurs launch an industry.
Endpoints News Executive Editor Drew Armstrong leads a conversation on China biopharma at the Financial Times summit, with Susan Winckler, CEO of the Reagan-Udall Foundation for the FDA, and Caitlin Frazer, executive director of the National Security…
Co-sponsored by XPRIZE Healthspan and ARPA-H's PROSPR program, this public meeting — convened by the Reagan-Udall Foundation for the FDA — will bring together FDA leadership, select awardees, academic researchers, product developers, clinicians, and…
The U.S. biotech industry is facing a major global rival for the first time. In response to the Chinese life science industry’s rapid growth, U.S. policymakers and regulators are racing to support Western innovation while maintaining patient safety.
Oncology clinical trials represent a dynamic frontier where site selection optimization directly influences the pace of innovation and the relevance of therapeutic advances.